Background: In 2013, Turkey introduced one-dose universal varicella vaccination (UVV) at 12 months of age. Inclusion of a second dose is being considered.
Methods: We developed a dynamic transmission model to evaluate three vaccination strategies: single dose at 12 months (1D) or second dose at either 18 months (2D-short) or 6 years of age (2D-long). Costs and utilization were age-stratified and separated into inpatient and outpatient costs for varicella and herpes zoster (HZ). We ran the model including and excluding HZ-related costs and impact of exogenous boosting.
Results: Five years post-introduction of UVV (1D), the projected varicella incidence rate decreases from 1,674 cases pre-vaccine to 80 cases/100,000 person-years. By 25 years, varicella incidence equilibrates at 39, 12, and 16 cases/100,000 person-years for 1D, 2D-short, and 2D-long strategies, respectively, using a highly effective vaccine. With or without including exogenous boosting impact and/or HZ-related costs and health benefits, the 1D strategy is least costly, but 2-dose strategies are cost-effective considering a willingness-to-pay threshold equivalent to the gross domestic product. The model predicted a modest increase in HZ burden during the first 20-30 years, after which time HZ incidence equilibrates at a lower rate than pre-vaccine.
Conclusions: Our findings support adding a second varicella vaccine dose in Turkey, as doing so is highly cost-effective across a wide range of assumptions regarding the burden associated with varicella and HZ disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692038 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220921 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus.
Neurol Neuroimmunol Neuroinflamm
January 2025
From the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.
Article Synopsis
- - The study investigates the relationship between the Epstein-Barr virus (EBV) and multiple sclerosis (MS) by analyzing the presence of antibodies against EBV and other common microbes in patients with MS, revealing a universal EBV seroprevalence among participants.
- - A total of 50 MS patients were tested for antibodies in their cerebrospinal fluid (CSF) and serum, finding that while all patients were EBV positive, the production of specific antibodies in the CSF was significantly lower for EBV compared to other viruses like measles and VZV.
- - The results indicate that even though almost all MS patients have been exposed to EBV, the actual production of antibodies against EBV in the central
An increase in the number of herpes zoster patients has been reported since universal varicella immunization was introduced, perhaps because of reduced opportunities for varicella patients to experience the natural booster effect caused by reexposure. We investigated recent trends of varicella zoster virus (VZV)-related central nervous system (CNS) infections at a university hospital in Japan. We enrolled patients with suspected CNS infection during 2013-2022 and tested cerebrospinal fluid samples by real-time PCR for DNA from 7 human herpesviruses.
View Article and Find Full Text PDFDevelopment of Indian Council of Medical Research (ICMR) Standard Treatment Workflows for Skin Diseases: A Step Toward Universal Health Coverage.
Indian Dermatol Online J
July 2024
Secretary to Government of India, Department of Health Research, and Director General, ICMR New Delhi, India.
Article Synopsis
- Skin conditions are prevalent but poorly managed, especially due to a shortage of dermatologists and unequal healthcare access between urban and rural areas.
- The objective was to create standard treatment workflows (STWs) for common skin diseases to help healthcare providers at all levels deliver better care.
- Thirteen modules covering various skin conditions were developed and are now available as posters in health centers and online, aiming to improve the treatment of skin diseases throughout the healthcare system.
A population database analysis to estimate the varicella vaccine effectiveness in children < 14 years in a high vaccination coverage area from 2004 to 2022.
Vaccine
December 2024
Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padua, 35131, Padua, Italy.
Introduction: In the Veneto Region of Italy, universal varicella vaccination (VV) started in 2007 with a two-dose schedule at 12-15 months and 5-6 years of age achieving 90 % coverage in 2019. The study aimed at evaluating the vaccine effectiveness (VE) in children using a primary-care database METHODS: This retrospective analysis used Pedianet, a comprehensive database of 73 family paediatricians in the Veneto Region. Incidence rates (IR) of varicella were evaluated in children aged <14 years enrolled since birth, between January 2004 to April 2022.
View Article and Find Full Text PDFPediatric Varicella-related Hospitalization in Turkey Between 2008 and 2018: Impact of Universal Single Dose Varicella Vaccine (VARICOMP Study).
Pediatr Infect Dis J
January 2025
Hacettepe University Faculty of Medicine, Department of Pediatric Infectious Diseases, Ankara, Turkey.
Article Synopsis
- In Turkey, a single-dose varicella vaccine was introduced in February 2013, aiming to reduce hospitalizations related to chickenpox among children under 18 years old.
- A study analyzed hospitalization data from 2008 to 2018, comparing rates before and after the vaccine's introduction, finding a significant decrease in hospitalizations (3.79 to 2.87 per 100,000 children per year).
- The most notable reduction was in children aged 1-5 years, with a 60.2% drop in hospitalizations post-vaccine, demonstrating the vaccine's effectiveness in preventing severe cases of varicella.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!